Article
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
The Journal of infectious diseases - 14 Sept 2020
Anthony Donald D, Sulkowski Mark S, Smeaton Laura M, Damjanovska Sofi, Shive Carey L, Kowal Corinne M, Cohen Daniel E, Bhattacharya Debika, Alston-Smith Beverly L, Balagopal Ashwin, Wyles David L
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved. METHODS: We conducted a nonrandomized clinical trial of 12 or 24 weeks of paritaprevir-ritonavir-ombitasvir plus dasabuvir (PrOD) with or without ribavirin in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.